近一个月超百只基金限购，业绩高增为何主动“踩刹车”？

Group 1 - The recent trend of limiting large subscriptions for high-performing funds is a response to the A-share market's recovery, with the Shanghai Composite Index stabilizing above 3600 points and reaching a year-to-date high [1][2] - As of August 11, over 133 funds have announced the suspension of large subscriptions, primarily those with outstanding performance and rapid growth in scale, with more than 40% of active equity funds achieving returns over 30% in the past year [2][3] - The proactive limitation of fund sizes is seen as a prudent measure to ensure the effectiveness of investment strategies and the stability of fund operations, while also cooling down excessive market enthusiasm [1][4] Group 2 - The fund "China Europe Medical Innovation," managed by renowned fund manager Ge Lan, has implemented a daily subscription limit of 100,000 yuan, marking a significant reduction from previous limits [2][3] - The rapid growth of fund sizes is evident, with some funds experiencing increases of over 10 times, such as Hai Fu Tong Quantitative Vanguard A and Guo Fu Zhao Rui You Xuan A, which had sizes below 60 million yuan at the end of last year [3][4] - The current market dynamics are supported by a surge in individual investor participation, with 14.56 million new accounts opened this year, a 36.9% increase year-on-year, and a significant rise in financing balances [6][7] Group 3 - The A-share market is expected to continue its upward trend, with liquidity support remaining strong, although there may be short-term adjustments due to market conditions [6][7] - The innovation drug sector is transitioning into a phase where actual performance will be tested, with companies that can secure good business development collaborations likely to stand out [8] - Attention is drawn to sectors with improving performance, such as orthopedic and innovative drug upstream companies, as well as medical devices, which may present investment opportunities [8]